Observations on the Efficacy and Economic Evaluation of Two-combina-tion Therapy of Voronasan and PPI in the First Eradication of Helicobacter Pylori Infection
OBJECTIVE Comp arison of the efficacy and pharmacoeconomics of helicobacter pylori(Hp)infec-tion eradication by voronasan duotherapy and proton pump inhibitor(PPI)duotherapy.METHODS A retrospec-tive collection of patients diagnosed with Hp infection and treated with dual therapy from March 2023 to June 2023 who met the criteria for natriuresis were divided into three groups according to the medication regimen,and all pa-tients were given a course of medication for 14 days.The treatment regimen was divided into Group A:amoxicillin(1.0 g/d tid or 0.75 g/d qid)in combination with voronasan(20 mg,bid);Group B:amoxicillin in combination with rabeprazole(20 mg,bid or 10 mg,qid);and Group C:amoxicillin in combination with esomeprazole(40 mg,bid or 20 mg,qid).The 13 C-urea breath test was repeated after 4-8 weeks of drug withdrawal to observe the Hp eradica-tion rate and the incidence of adverse reactions in the three groups,respectively,and to analyze the economics of the three regimens.RESULTS A total of 174 study subjects were included,including 85 males and 89 females,with an average age of(45.32±13.20)years.A total of 163 cases(64 cases in Group A,48 cases in Group B,and 51 cases in Group C)completed the test.Intentionality analysis(ITT)(89.71％vs 92.16％vs 90.91％)and protocol set compliance analysis(PP)(90.63％vs 91.67％vs 90.20％)showed that the differences in Hp eradication rates a-mong the three groups were not statistically significant(P＞0.05),and there were no significant differences in the incidence rates of adverse reactions among the three groups(P＞0.05).The three treatment regimens were based on least-cost analysis,Group A(cost RMB 277.20)＜Group C(cost RMB 458.64)＜Group B(cost RMB 553.28),and Group A voransen group was the most economically significant treatment regimen,with consistent results after sensitivity analysis.CONCLUSION Vonorasan diathermy can be used as an alternative to PPI duotherapy,with lower costs and economic advantages compared to rabeprazole and esomeprazole duotherapy.
万方数据
维普
